Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中Selleckの製品使用例(64)

カスタマーフィードバック(13)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NIXOcmtEgXSxdH;4bYMhSXO|YYm= M3vrV|ExKG6P M{PTOlczKGh? MVfEUXNQ NV;xRXh2WG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MX6yOFkxODh5Mx?=
HT-29 NVjJd3lLS3m2b4TvfIlkKEG|c3H5 MUCxNEBvVQ>? MnH4O|IhcA>? MljDSG1UVw>? M1LkOHBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= NU\xPI5GOjR7MEC4O|M>
HT-29 MVrDfZRwfG:6aXOgRZN{[Xl? NYfrVo1KOTBibl2= MnzkO|IhcA>? NVu1fZZFTE2VTx?= M{fMRnBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M4i0TFI1QTByOEez
PC3 NGDBd2dMcW6jc3WgRZN{[Xl? M1\FWFExOCCwTR?= MUSxJIg> Mo\tSG1UVw>? MkfxVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= NY\0VYljOjF7N{i2PFM>
PC3 NITsb|FMcW6jc3WgRZN{[Xl? MmT3NVAxKG6P MWKxJIg> NUPtfIpITE2VTx?= MV;Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NFLXR|IzOTl5OE[4Ny=>
PC3 NGrIVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3xNU42KM7:TR?= NYLHellUOSCq M4ixbmROW09? NFzzZXZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= MWqyNVk4QDZ6Mx?=
HEK293 MWXGeY5kfGmxbjDBd5NigQ>? MXixNFAhdk1? NXLyZnNsQCCq MojVSG1UVw>? MYXJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? M3vyR|IyPTN7M{Cx
BT-20 M2XpW2tqdmG|ZTDBd5NigQ>? NHPtNZIzOCEQvF2= MmfVSG1UVw>? MVHEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MmTNNlE{PTN3NUG=
U937 NF\YPGJCdnSrYnHjeIVzcWGuIFHzd4F6 NGSxWos2OCEQvF2= NULudIlZPDhiaB?= M3vBNWROW09? M4nqWWlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= M3TzclIyOTR{MUC2
U937 NETIdJpCdnSrYnHjeIVzcWGuIFHzd4F6 NXLHNlIxPTBizszN NHzZNIY1QCCq Mmr6SG1UVw>? MmrmSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MlzyNlEyPDJzME[=
U937 MkPoRY51cWKjY4TldolidCCDc4PhfS=> NXfCdmU4PTBizszN NX;T[YhSPDhiaB?= MYHEUXNQ MWjEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MViyNVE1OjFyNh?=
MCF-7 M{fBPGF2fG:yaHHnfUBCe3OjeR?= NY\WWGttOzBibl2= MYe0JIg> MXfEUXNQ M4j5Tmlv\HWlZYOgZZV1d3CqYXf5 MnTYNlAxOjhzM{S=
U87MG M1\Ce2tqdmG|ZTDBd5NigQ>? NVGwcVVxOSEQvF2= MXe2JIg> M2ntOGROW09? MVjQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? NXXtPINQOTl6NEi0NFQ>
U87MG MlO2T4lv[XOnIFHzd4F6 MYixJO69VQ>? M4PCdVYhcA>? M2\nVGROW09? MXHQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NYHUb3FLOTl6NEi0NFQ>
U87MG MWHLbY5ie2ViQYPzZZk> M4HZW|Eh|ryP MlPJOkBp MY\EUXNQ MnLMSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MXqxPVg1QDRyNB?=
U87MG NVP0WY45U2mwYYPlJGF{e2G7 NHjDdnAyKM7:TR?= NFTqNGg3KGh? MnLxSG1UVw>? MVPEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NI\lUo0yQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb M32yPGF2fG:yaHHnfUBCe3OjeR?= MYOwMlIh|ryP M1e2WVI1KGh? NGfwZo1FVVOR MljaTY5lfWOnczDheZRweGijZ4m= MkDhNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 NYn6UmE3SXW2b4DoZYd6KEG|c3H5 NI\hcHcxNjJizszN MoO4NlQhcA>? MnfYSG1UVw>? NWCxR2x4UW6mdXPld{BifXSxcHjh[5k> NInFeosyQDN7MUm0PS=>
H4 M{\FVmZ2dmO2aX;uJGF{e2G7 NFK5eHYxNjJizszN M3XSS|I1KGh? MlqzSG1UVw>? NUPFNlhRUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? M1jEVVE5ODJ2NUi0
HeLa MWPGeY5kfGmxbjDBd5NigQ>? NV;yZYRvOTByIH7N NVPB[lZNOzZiaB?= NVrzNIUxTE2VTx?= MkHGTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MV[xO|U3OzN6NR?=
HeLa NUHPNYpyTnWwY4Tpc44hSXO|YYm= MWKxNFAhdk1? NYjmZYZHOzZiaB?= NUi0S3NtTE2VTx?= NGrMRldKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? MVqxO|U3OzN6NR?=
HeLa MYHGeY5kfGmxbjDBd5NigQ>? MYexNFAhdk1? MmLTN|YhcA>? M1TCPWROW09? M4L0W2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> Mme2NVc2PjN|OEW=
SYF M{jZdWZ2dmO2aX;uJGF{e2G7 MorzNVAxKG6P MlHINlQhcA>? NIfOOFRFVVOR MnPCTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MmfnNVc2PjN|OEW=
SYF NXfkT2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF20TI0yODBibl2= M{H0SVI1KGh? NX3UTJB2TE2VTx?= NGe0W2dKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NETIc|MyPzV4M{O4OS=>
HEK293T NF3ic41CdnSrdnnyZYwhSXO|YYm= NWrHdJplOSCwTR?= MoO1OEBl NFzYSmtFVVOR NVjufotwUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> MVyxO|Q5PTVyMR?=
HEK293T NEXVV29CdnSrdnnyZYwhSXO|YYm= NHTRdncyKG6P M1;4ZlQh\A>? Mn\wSG1UVw>? M13oNWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N M1nROVE4PDh3NUCx
PBMC NXjtOFYzTnWwY4Tpc44hSXO|YYm= NEjoW5oyKG6P NX3aeZlNOTRiZB?= NVPhUnNwTE2VTx?= NF;Hc41T\WS3Y3XzJGNEWjViZHXud4l1gQ>? MWKxO|Q5PTVyMR?=
PBMC MnHtSpVv[3Srb36gRZN{[Xl? Ml3INUBvVQ>? Ml20NVQh\A>? M13XV2ROW09? MWXEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> NIDo[WIyPzR6NUWwNS=>
HEK293 cells NH;hOpFMcW6jc3WgRZN{[Xl? M3TqfVUxKG6P NVrjUFc3PDVibXnu MmGzSG1UVw>? NHfXSIpKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P NHS5eGwyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NUCwPXdyTnWwY4Tpc44hSXO|YYm= M3Hl[FExOCCwTR?= MVK0JIg> NUKxRpRZTE2VTx?= MYHJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> M{Hx[|E4OTJ6Mk[y
Human mixed lymphocyte M1nOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXaV5Q2KG6P NXK2dI9mTE2VTx?= MnTmTWM2OD1zLk[gcm0v MUGxOlE5PTh4NR?=
Lewis rat lymph node cells MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG4WFg2KM7:TR?= NEDlNI9FVVOR MmmyTWM2OD1{Lk[g{txO NUP6V4lmOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice NVTyWFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raZlExKG6P MoTnO|IhcA>? Mm\TSG1UVw>? NYPvcIlxUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> MYixNFAzOTl2OB?=
MRK-nu-1 NYTSbFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnzZ5NjUUN3ME2wMlg1PSCyTR?= MljDV2FPT0WU
OCUB-M MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrSfpNKSzVyPUWuNlQheE1? MX;TRW5ITVJ?
SF539 M{foc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\sTWZQUUN3ME2xNU43KHCP M3rGT3NCVkeHUh?=
ES4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH4TWM2OD1{MT61JJBO NUT2coZ1W0GQR1XS
RL95-2 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;lUVVoUUN3ME2xNFcheE1? MVPTRW5ITVJ?
LC-2-ad NVrVc4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPOOVFKSzVyPUSyN{BxVQ>? MX7TRW5ITVJ?
Daudi MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDp[lRDUUN3ME20N|QheE1? Ml;aV2FPT0WU
NTERA-S-cl-D1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nx[2lEPTB;NESzJJBO NFLlVnlUSU6JRWK=
OS-RC-2 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LWRWlEPTB;NkWyJJBO M{jWT3NCVkeHUh?=
VA-ES-BJ NVj2eIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj3TWM2OD15MkOgdG0> NHOyRnFUSU6JRWK=
GR-ST MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTh2NjDwUS=> MV7TRW5ITVJ?
SW872 NXiycGxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm3[4pvUUN3ME24OFYheE1? NH\TS2dUSU6JRWK=
NOS-1 NH3CUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPCTWM2OD16N{GgdG0> MXvTRW5ITVJ?
MC116 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTiTZZKSzVyPUm4OUBxVQ>? Mki4V2FPT0WU
NCI-H1355 NHeyW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMEGgcm0> NVnlUpVpW0GQR1XS
RPMI-8226 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:4VGlEPTB;MT6xPUBvVQ>? M2PLTnNCVkeHUh?=
TE-15 NWrnOJQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q4TmlEPTB;MT6zOkBvVQ>? NXzZUItIW0GQR1XS
Ramos-2G6-4C10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjXW3RGUUN3ME2xMlQ3KG6P NVzWSXc6W0GQR1XS
KU812 NWDJT2s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwMEGgcm0> M33DfXNCVkeHUh?=
EW-1 NVy2SFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwMUegcm0> NV3URYRNW0GQR1XS
KS-1 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDOdotKSzVyPUKuOFUhdk1? MWLTRW5ITVJ?
SK-LMS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfUZ5BKSzVyPUKuOFkhdk1? MX;TRW5ITVJ?
TGBC1TKB M1;rOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTGPIpJUUN3ME2yMlY6KG6P MkLSV2FPT0WU
TE-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHWTWM2OD1{Lke3JI5O MXnTRW5ITVJ?
ETK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofDTWM2OD1{LkiyJI5O MWrTRW5ITVJ?
BE-13 NULmPGZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TMcWlEPTB;Mj65PUBvVQ>? MY\TRW5ITVJ?
A3-KAW NIHQU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TiWWlEPTB;Mj65PUBvVQ>? MkjJV2FPT0WU
TE-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfRPWlKSzVyPUOuN{BvVQ>? M1XFXHNCVkeHUh?=
DOHH-2 NX:0UFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn5PWRKSzVyPUOuN|Uhdk1? NV72UXQxW0GQR1XS
ES6 M4i3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjJcpBIUUN3ME2zMlQ{KG6P MXLTRW5ITVJ?
OPM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwMUWgcm0> NGrTV4RUSU6JRWK=
SH-4 M363[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHrTWM2OD12LkO0JI5O MXnTRW5ITVJ?
NB13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRwM{[gcm0> NVXlR4d5W0GQR1XS
HUTU-80 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLTNI86UUN3ME20MlQzKG6P NIrUPWlUSU6JRWK=
CCRF-CEM MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXwPWFKSzVyPUSuPVQhdk1? NIj0XoZUSU6JRWK=
TGBC24TKB MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;0ZmlEPTB;NT61NUBvVQ>? M2C2Z3NCVkeHUh?=
697 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[3U2lEPTB;Nj6yPEBvVQ>? NV7WXWM6W0GQR1XS
J-RT3-T3-5 NIm0bZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHMbVBDUUN3ME22MlQ3KG6P NWDzXnpvW0GQR1XS
KALS-1 NGLaUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTZwNU[gcm0> MUDTRW5ITVJ?
no-10 NHyw[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTdwMkmgcm0> M{fYUnNCVkeHUh?=
SK-NEP-1 NITCOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRThwN{mgcm0> NFnHboJUSU6JRWK=
L-540 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rvO2lEPTB;MUCuOFIhdk1? NGHuOWtUSU6JRWK=
JiyoyeP-2003 NFv2dYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH2SXBKSzVyPUGwMlk1KG6P M{C3TnNCVkeHUh?=
HH NXricXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr0UIdKSzVyPUGxMlM6KG6P MXjTRW5ITVJ?
SR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzfoNKSzVyPUGxMlQ2KG6P M2XPXnNCVkeHUh?=
QIMR-WIL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnTW3d2UUN3ME2xNU45PSCwTR?= M{\QSHNCVkeHUh?=
A4-Fuk NYPiPFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF|LkGyJI5O Mkj6V2FPT0WU
CESS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjrfZRnUUN3ME2xN{4yOyCwTR?= M1f2bHNCVkeHUh?=
KE-37 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF4LkC3JI5O MWrTRW5ITVJ?
SK-UT-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF4LkixJI5O M3W5eXNCVkeHUh?=
SIG-M5 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTzTWM2OD1zNz6yOUBvVQ>? NVXX[4hiW0GQR1XS
HT MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG0OpJRUUN3ME2xO{43KG6P NVzUcplzW0GQR1XS
DEL NHyz[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPQdG5bUUN3ME2xO{46QSCwTR?= NG\4eWtUSU6JRWK=
SK-PN-DW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX5dFdKSzVyPUKwMlI{KG6P M4jnRnNCVkeHUh?=
RPMI-8402 M3zhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnrOmFRUUN3ME2yNU44PyCwTR?= NInqb2tUSU6JRWK=
RPMI-6666 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3rTWM2OD1{ND60NkBvVQ>? NHTyd29USU6JRWK=
NCI-H720 NYjFSopkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfL[WhKSzVyPUK1MlQyKG6P NXfKNnE{W0GQR1XS
EW-16 M37COWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV61U4FSUUN3ME2yOk45PyCwTR?= M3XWU3NCVkeHUh?=
BL-70 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ6LkO4JI5O M4Lq[3NCVkeHUh?=
SF126 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHrUGRNUUN3ME2zNE4{QCCwTR?= Mmq3V2FPT0WU
BC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNzLkK2JI5O NVLLN29HW0GQR1XS
MHH-PREB-1 M4D2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjTWmU3UUN3ME2zNk41PCCwTR?= MWLTRW5ITVJ?
A101D M{O3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fsPGlEPTB;M{KuOlIhdk1? MnLVV2FPT0WU
NMC-G1 M3HVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN|Lk[3JI5O MXLTRW5ITVJ?
LB1047-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTN2Lk[5JI5O M4nqb3NCVkeHUh?=
EM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PyWWlEPTB;M{iuOVMhdk1? MlLiV2FPT0WU
COLO-684 NYPyO|E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnyPGo2UUN3ME2zPU45KG6P MkPCV2FPT0WU
Becker MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLDTWM2OD12MT6wOUBvVQ>? Mkf0V2FPT0WU
BL-41 NHvuSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTR|Lk[2JI5O NHHoSnJUSU6JRWK=
MDA-MB-134-VI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnY[mpKSzVyPUS0MlAzKG6P NV7rRXVrW0GQR1XS
L-363 M3XzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyzWmFKSzVyPUS0Mlc{KG6P M{PI[nNCVkeHUh?=
ECC4 NFXTSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR2Lke4JI5O NF3nWnRUSU6JRWK=
A388 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHGTWM2OD12ND64NkBvVQ>? NHriUnJUSU6JRWK=
HEL MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR7Lke5JI5O MX7TRW5ITVJ?
RKO NH;1V29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iwbWlEPTB;NUCuNlkhdk1? MYjTRW5ITVJ?
KINGS-1 M3y1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;NPHlyUUN3ME21NU42PSCwTR?= Mn:4V2FPT0WU
EB-3 NFj0bG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGyVXFKSzVyPUWyMlY4KG6P MnPnV2FPT0WU
ARH-77 NEnoXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTV{Lkigcm0> M33YO3NCVkeHUh?=
GCIY M2LjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTV|LkS2JI5O M4rGR3NCVkeHUh?=
NCI-H1304 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrwdVhKSzVyPUW3MlIzKG6P NVH6[nNqW0GQR1XS
KARPAS-299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor0TWM2OD14MT64NkBvVQ>? M1naR3NCVkeHUh?=
IA-LM NHTrW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzndVU1UUN3ME22PE4yOyCwTR?= MWXTRW5ITVJ?
GI-1 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfnZWdbUUN3ME23NE4{QSCwTR?= Mn;hV2FPT0WU
TE-11 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUexXmhtUUN3ME23O{4yPyCwTR?= MkH0V2FPT0WU
LS-411N Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfjeZdHUUN3ME23O{42PyCwTR?= MV;TRW5ITVJ?
no-11 NYHiZpZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PX[2lEPTB;OEOuNlQhdk1? MUfTRW5ITVJ?
MV-4-11 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTBTWM2OD16Mz63N{BvVQ>? MmHNV2FPT0WU
BV-173 NYLJXGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[yTWM2OD16Mz65O{BvVQ>? MYrTRW5ITVJ?
CMK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrWVWFKSzVyPUi0MlE3KG6P M4nrZXNCVkeHUh?=
LC4-1 NEfGSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTh4LkeyJI5O MlXmV2FPT0WU
COR-L279 NEewfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTh5LkK1JI5O MYXTRW5ITVJ?
NCI-H209 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S1XWlEPTB;OEeuOFEhdk1? MVjTRW5ITVJ?
Raji MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjFXHpKSzVyPUi5MlczKG6P M{LiOnNCVkeHUh?=
LB996-RCC MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPpTWM2OD17Mz60N{BvVQ>? MoHNV2FPT0WU
NCI-H526 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\YTWM2OD17Mz61PUBvVQ>? MUDTRW5ITVJ?
KGN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXZWlEPTB;OU[uNlkhdk1? MlLFV2FPT0WU
MOLT-4 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vHcGlEPTB;OU[uO|khdk1? MVzTRW5ITVJ?
PF-382 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jNNWlEPTB;OU[uO|khdk1? NXv6bJdEW0GQR1XS
BC-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWTWlEPTB;OUmuNVghdk1? NEXuTZFUSU6JRWK=
KARPAS-422 NIrtflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XCXmlEPTB;MUCyMlA6KG6P M3nQNnNCVkeHUh?=
SBC-1 NEHobWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTjTWM2OD1zMEeuO|Uhdk1? NEPBPWpUSU6JRWK=
LC-1F M{LDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELo[Y9KSzVyPUGwPE4xPSCwTR?= M2XEdHNCVkeHUh?=
GB-1 M3;rPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu2TWM2OD1zMEmuNFIhdk1? MlWxV2FPT0WU
SNB75 NVSyZXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrM[2dmUUN3ME2xNVkvPjlibl2= NVXtNIxrW0GQR1XS
BB65-RCC M{nKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjaSlhnUUN3ME2xNVkvQTNibl2= NH\iWG5USU6JRWK=
NCI-N87 NIHidlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTXTWM2OD1zMkGuPVghdk1? MY\TRW5ITVJ?
IST-MEL1 M3LOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF{Mj6zPEBvVQ>? MYnTRW5ITVJ?
HOP-62 NFzueppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33mdmlEPTB;MUK2Mlg6KG6P Mo\zV2FPT0WU
ACN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL0TWM2OD1zNE[uO|Uhdk1? MVvTRW5ITVJ?
DMS-114 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF3MD62O{BvVQ>? M4jPcHNCVkeHUh?=
MLMA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hqc2lEPTB;MUW5Mlg5KG6P M2TaRnNCVkeHUh?=
HT-144 M3q3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrIcog1UUN3ME2xOlUvPDNibl2= Mnj6V2FPT0WU
C2BBe1 NUnPb3BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HDVWlEPTB;MU[3Mlc3KG6P M4T6WnNCVkeHUh?=
L-428 M4DLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF5Nz63JI5O NInvbFhUSU6JRWK=
DU-4475 NG\5[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XWXGlEPTB;MUi3MlY5KG6P MYLTRW5ITVJ?
CP67-MEL NF\BdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF7OT6zPEBvVQ>? M{\ZSHNCVkeHUh?=
MEG-01 NEHSPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnqNZFwUUN3ME2yNFEvQTZibl2= M3j4fnNCVkeHUh?=
IST-SL2 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKwXGtKSzVyPUKwPE43OyCwTR?= M3fJZXNCVkeHUh?=
ES8 M3z1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ra[GlEPTB;MkK1Mlk1KG6P M13QWHNCVkeHUh?=
COLO-800 NXrreYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLOb5FKSzVyPUKzOU4zQCCwTR?= Mli4V2FPT0WU
MFH-ino NFfEeYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X3dWlEPTB;MkO1Mlg1KG6P NUH6TWJZW0GQR1XS
OVCAR-4 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn3b5VKSzVyPUKzO{4zPCCwTR?= M1LPZ3NCVkeHUh?=
PSN1 MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3UOXpqUUN3ME2yOFIvPzFibl2= MV7TRW5ITVJ?
EW-12 NHzwOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ2Mz6xJI5O NFXseYRUSU6JRWK=
HCC1599 NXy1dHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjtW5BKSzVyPUK2NU41PyCwTR?= M3PSc3NCVkeHUh?=
SJSA-1 M1\H[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojmTWM2OD1{N{GuOFYhdk1? M2n5S3NCVkeHUh?=
ST486 NInu[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ7Nj6xOEBvVQ>? MlrxV2FPT0WU
NOMO-1 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNyMD6yNUBvVQ>? Ml\UV2FPT0WU
MN-60 NGHuNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknFTWM2OD1|MEWuN|Ihdk1? MnLxV2FPT0WU
HCC1187 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS3S4s{UUN3ME2zNFcvOjVibl2= MnO1V2FPT0WU
SW982 M1\pWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnjVY5KSzVyPUOxOE44PSCwTR?= NWrxW5FmW0GQR1XS
LB647-SCLC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\UeXlKSzVyPUOyPE44OSCwTR?= MoDUV2FPT0WU
HC-1 NILY[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP5XGJKSzVyPUOzOU42KG6P MUfTRW5ITVJ?
EHEB MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhboJKUUN3ME2zN|cvPTJibl2= Mon2V2FPT0WU
TUR Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN4Mz65OUBvVQ>? M3rtUXNCVkeHUh?=
LU-139 M{X4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q4NWlEPTB;M{e4MlAzKG6P M2O5TnNCVkeHUh?=
NB1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K4TGlEPTB;M{i0MlQ2KG6P MXTTRW5ITVJ?
BB30-HNC NV3qVpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGWFZKSzVyPUO4PE4{OiCwTR?= MmPNV2FPT0WU
HAL-01 NGHreIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX75eXJGUUN3ME2zPFkvOjZibl2= MlHXV2FPT0WU
K5 M{fJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi2Tng4UUN3ME20NVEvOzdibl2= MWTTRW5ITVJ?
MZ2-MEL M{nybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvSmlEPTB;NEGzMlY1KG6P M1vBfnNCVkeHUh?=
RXF393 NX7xeJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRzNj60OUBvVQ>? MlvDV2FPT0WU
NCI-H1648 M3TpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSTWM2OD12MUeuOVMhdk1? MlLtV2FPT0WU
TE-12 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR|ND6yOkBvVQ>? NUfPSJRFW0GQR1XS
EoL-1- NYfHN2pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DFSGlEPTB;NEO3Mlk5KG6P NUDIVVJDW0GQR1XS
JAR NXLNbWlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR|OD62NkBvVQ>? NGDyd5dUSU6JRWK=
DSH1 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR3OD65NUBvVQ>? MojUV2FPT0WU
NCI-H187 NHXLXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTR4Mj64NUBvVQ>? NVrFXVRoW0GQR1XS
HCE-4 NXvBeIZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TTb2lEPTB;NEe3MlY3KG6P NWHuUmxMW0GQR1XS
8-MG-BA MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPneZJ2UUN3ME21PFEvPTJibl2= M3WzOnNCVkeHUh?=
KLE NEjZ[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXjSGpKSzVyPUW4OU4zKG6P MXfTRW5ITVJ?
KNS-42 NFfXbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTV6Nj64NUBvVQ>? M4LE[nNCVkeHUh?=
MSTO-211H NXGxfot[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZyOT63OEBvVQ>? M3PVNnNCVkeHUh?=
GDM-1 NIjMfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfwcnpKSzVyPU[xOE4xQSCwTR?= MVHTRW5ITVJ?
TE-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTZ2Nj6xNkBvVQ>? NFzpWZdUSU6JRWK=
BT-474 NH[3[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTZ2Nz6wOkBvVQ>? NYfwR|VHW0GQR1XS
KARPAS-45 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz6TWM2OD14NEeuOkBvVQ>? MWHTRW5ITVJ?
MOLT-16 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXWZWpKSzVyPU[0O{46OyCwTR?= MoHwV2FPT0WU
KURAMOCHI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VXmJKSzVyPU[1O{42OSCwTR?= MXzTRW5ITVJ?
K-562 M4nWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTZ4OT61NUBvVQ>? MYDTRW5ITVJ?
EKVX NUXkdolsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXUfZRKUUN3ME22O|IvPzFibl2= MoTKV2FPT0WU
GAK MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTZ5NT6zJI5O MVLTRW5ITVJ?
NCI-SNU-5 NU[0cFBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\RNmlEPTB;NkmwMlAyKG6P NIDNfWVUSU6JRWK=
NCI-H2126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT3TWM2OD15Mk[uPFchdk1? MX;TRW5ITVJ?
CTV-1 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLRTWM2OD15NESuPUBvVQ>? MVvTRW5ITVJ?
SW962 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTd2OD60OEBvVQ>? NWSyOWVxW0GQR1XS
MONO-MAC-6 NULNN4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfONYt{UUN3ME23OVYvQTNibl2= NIfUTnBUSU6JRWK=
NCI-H748 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvrZ5NKSzVyPUe1PE46QSCwTR?= MkLRV2FPT0WU
NCI-H524 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPZ3NYUUN3ME23PFAvPzNibl2= MmDDV2FPT0WU
LS-123 NVPl[WF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHsU|JKSzVyPUe5OU43QSCwTR?= MlfCV2FPT0WU
NB7 NX63OJU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWewZpJMUUN3ME24NVQvOTRibl2= MkjPV2FPT0WU
LS-1034 M3jxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTh{OD65PEBvVQ>? NHvpcIJUSU6JRWK=
TE-5 M{DtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TuNmlEPTB;OEizMlU3KG6P M1zkOHNCVkeHUh?=
A704 NVXlOJpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xud2lEPTB;OEm5MlE2KG6P Mk\NV2FPT0WU
TK10 NI\YfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jqbWlEPTB;OUG2MlA{KG6P MV\TRW5ITVJ?
NCI-H345 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fZd2lEPTB;OUSzMlIzKG6P MYnTRW5ITVJ?
CGTH-W-1 NFTpcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HIXmlEPTB;OUS4MlE{KG6P NIW2RVZUSU6JRWK=
NCI-H510A NGX2XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTl6NT6xNkBvVQ>? NFe2ZYhUSU6JRWK=
NCI-H1963 M{PxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6zTWM2OD1zLkCzNlkzKM7:TR?= MnjKV2FPT0WU
SCC-3 NWL5PXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK1R|lWUUN3ME2xMlA{PDF2IN88US=> M3m3cHNCVkeHUh?=
EW-11 NGi5U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\xcGlEPTB;MT6wPFc1OyEQvF2= MVjTRW5ITVJ?
CPC-N NGruOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HtXGlEPTB;MT6wPFgh|ryP NYrGSm1UW0GQR1XS
NCI-H1417 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33xe2lEPTB;MT6xNlI3KM7:TR?= NEHTZ5ZUSU6JRWK=
DG-75 M{iwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jzV2lEPTB;MT6xOlI5PSEQvF2= NWDXbm4zW0GQR1XS
HD-MY-Z MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDkZnJKSzVyPUGuNVY1OTZizszN MVPTRW5ITVJ?
ATN-1 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DJVWlEPTB;MT6yOlIxQSEQvF2= MXzTRW5ITVJ?
KM-H2 M17UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwMk[0NFgh|ryP NXLXeFIzW0GQR1XS
NCI-H2081 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzHbWVCUUN3ME2xMlI3PjN5IN88US=> M3vEOnNCVkeHUh?=
HL-60 NEW0NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\3fWlEPTB;MT6yOlk2QSEQvF2= NFr0SZFUSU6JRWK=
DB NFPmTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\2[pczUUN3ME2xMlI4OjR{IN88US=> NYXSNnYzW0GQR1XS
NCI-H1522 M3K3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC3[GNEUUN3ME2xMlI5QDh5IN88US=> NFy4VopUSU6JRWK=
AM-38 NGK0cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImzZmNKSzVyPUGuN|A4OiEQvF2= M{i2SXNCVkeHUh?=
NCI-H446 NInl[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPacplKSzVyPUGuN|IyOjFizszN MXfTRW5ITVJ?
SU-DHL-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwM{K4NFEh|ryP NEHlZppUSU6JRWK=
NH-12 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjTTWM2OD1zLkO2N|c1KM7:TR?= MVfTRW5ITVJ?
DMS-79 NHTO[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33KSGlEPTB;MT6zOlg3PiEQvF2= NUHIWXVvW0GQR1XS
NCI-H716 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4PXZKSzVyPUGuN|g6QDZizszN MYrTRW5ITVJ?
ML-2 NELSOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT1TWM2OD1zLkSxOVI6KM7:TR?= NV\lO3ZpW0GQR1XS
NB10 NFPReoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3CVFVKSzVyPUGuOFY3OzJizszN NH20OWFUSU6JRWK=
ONS-76 NGK4S3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwNUO1Olkh|ryP NIfaOZpUSU6JRWK=
LOUCY NYDlXnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjYTWM2OD1zLkW0OlU4KM7:TR?= MWDTRW5ITVJ?
SCLC-21H MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq2VnpKSzVyPUGuOVg2QDJizszN MofmV2FPT0WU
TGW M3myOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTxTWM2OD1zLk[zPVc2KM7:TR?= MkD4V2FPT0WU
LXF-289 NGn4cVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:0TWM2OD1zLkezNlY5KM7:TR?= NULyfVREW0GQR1XS
BB49-HNC NHLzOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwN{O1PFYh|ryP NUXYWWVCW0GQR1XS
NCI-H747 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3DTWM2OD1zLke1N|Q3KM7:TR?= NWXSRmR7W0GQR1XS
LU-165 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L3dGlEPTB;MT64OFk5PiEQvF2= NG[xelVUSU6JRWK=
OMC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLvNGZKSzVyPUGuPVUxPjZizszN NFLsfnpUSU6JRWK=
RCC10RGB NXq3cHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfjTWM2OD1zLkm1PFE4KM7:TR?= NYTOS|VmW0GQR1XS
SW684 M4TXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LZdGlEPTB;MT65OlA6QSEQvF2= NFu4dIJUSU6JRWK=
TE-8 NYq2ZYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT5SWFKSzVyPUKuNFU2PTlizszN M2jqc3NCVkeHUh?=
SK-N-DZ MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;3b2lEPTB;Mj6xN|I4PCEQvF2= M{HtNnNCVkeHUh?=
EVSA-T MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD1{LkG3N|E2KM7:TR?= M3\R[XNCVkeHUh?=
KASUMI-1 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHVeHlVUUN3ME2yMlE5QDF3IN88US=> NEKxbGpUSU6JRWK=
NKM-1 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Lb2lEPTB;Mj6yOVQ4OiEQvF2= MkD4V2FPT0WU
CAL-148 NHLnUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP3NXZKSzVyPUKuN|M3OTRizszN MVHTRW5ITVJ?
NCI-H64 NGDYWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwM{SyN|Ih|ryP NUPqUVdXW0GQR1XS
KNS-81-FD NEPle3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr0SmtKSzVyPUKuN|Y3OiEQvF2= NUjMd5Z4W0GQR1XS
KM12 M1Llcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{POOGlEPTB;Mj60NFg{QSEQvF2= NEnYPXlUSU6JRWK=
SW954 NInSNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwNEe3O|kh|ryP MlHzV2FPT0WU
NCI-H1395 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXXPWdqUUN3ME2yMlUzPjR3IN88US=> NGjpbIRUSU6JRWK=
DJM-1 NI\GeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O5NWlEPTB;Mj62NFY{KM7:TR?= NEjIfolUSU6JRWK=
COLO-668 NFjKfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K5RWlEPTB;Mj64NlY6PSEQvF2= MXnTRW5ITVJ?
NCI-H1436 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjmOFVIUUN3ME2yMlg2PjF3IN88US=> NXG5O3FvW0GQR1XS
LB2241-RCC M2jC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrwboJKSzVyPUKuPFY5OzlizszN NV\sdFhJW0GQR1XS
GT3TKB M4roR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fJXmlEPTB;Mj64PVA2PSEQvF2= MUPTRW5ITVJ?
COLO-824 NV;HeGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzlR2lLUUN3ME2yMlg6PzZ6IN88US=> NG\6OVVUSU6JRWK=
ES1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny1TWM2OD1{Lki5PFc6KM7:TR?= Mme3V2FPT0WU
LB771-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwOUC5OFYh|ryP MV3TRW5ITVJ?
GI-ME-N MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvTemFKSzVyPUOuNFA6ODRizszN NWnCdIJ2W0GQR1XS
NALM-6 NWf0cYlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnLTWM2OD1|LkCwPVM{KM7:TR?= MmDGV2FPT0WU
LU-134-A M3m2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC0TWM2OD1|LkC1OFI2KM7:TR?= MYXTRW5ITVJ?
DMS-153 NVO0dJpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTSdHdKSzVyPUOuNFU5OjRizszN NYW1Z2FUW0GQR1XS
MZ1-PC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\uR2lEPTB;Mz6wPVA4QCEQvF2= NGPNfHNUSU6JRWK=
NCI-H1155 M3jWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi2TJJ4UUN3ME2zMlEyPjFizszN MUnTRW5ITVJ?
CAS-1 NIraSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwMUO3NFch|ryP NFzrfnJUSU6JRWK=
D-502MG NXzrNmZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\2TWM2OD1|LkG0N|kh|ryP M{LRTnNCVkeHUh?=
NCI-H2141 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPNZpFKSzVyPUOuNVc1PTJizszN M4nBTnNCVkeHUh?=
NB6 M3vTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjUTWM2OD1|LkG4NlU6KM7:TR?= MnXiV2FPT0WU
NCCIT MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[xdmlEPTB;Mz6yNVgxQSEQvF2= MVTTRW5ITVJ?
NB69 NIHKUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwM{G4PVEh|ryP M4fRSHNCVkeHUh?=
JVM-2 M{H0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fjV2lEPTB;Mz6zOlQ{OyEQvF2= MXLTRW5ITVJ?
K052 NFrldoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwM{e5Olgh|ryP NYXkOnA1W0GQR1XS
HCC2157 M2rLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTETWM2OD1|LkWzNlI5KM7:TR?= NX7oSod5W0GQR1XS
KMOE-2 NHXnSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5fWlEPTB;Mz61OFI1OiEQvF2= MYjTRW5ITVJ?
SF268 M3rT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwN{G1OVQh|ryP NX;ndHhsW0GQR1XS
CHP-126 NWfQTm14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfzV3lxUUN3ME2zMlc3PDV6IN88US=> M1fSZ3NCVkeHUh?=
CP66-MEL NIjZZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTNTWM2OD1|Lke5NFk1KM7:TR?= M1HENnNCVkeHUh?=
NCI-H69 M3S5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS4WIV7UUN3ME20MlAyQTN4IN88US=> MVjTRW5ITVJ?
A253 NHPuVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK0TWM2OD12LkCyNVAyKM7:TR?= M3nzW3NCVkeHUh?=
NB14 NYHkWGRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRwMUC0O|kh|ryP NXPBOpo5W0GQR1XS
NCI-H1694 NWPVcVB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PI[WlEPTB;ND6xN|EyOiEQvF2= MmPIV2FPT0WU
NCI-H2196 NYLmWJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PMU2lEPTB;ND6xO|E3QSEQvF2= NHrtNmNUSU6JRWK=
TE-9 NIjadm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L2fGlEPTB;ND6xO|U5OiEQvF2= NImzRXFUSU6JRWK=
D-283MED NFPZNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvvT3JKSzVyPUSuNVg5PCEQvF2= NYP5c2tYW0GQR1XS
OCI-AML2 NXjjfYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYflW2plUUN3ME20MlE6PDh7IN88US=> M{LwNXNCVkeHUh?=
D-263MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;STWM2OD12LkKyPVYyKM7:TR?= MUDTRW5ITVJ?
MPP-89 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfWTWM2OD12LkK3N|A1KM7:TR?= MornV2FPT0WU
LAMA-84 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwM{C0NlEh|ryP NHy1TGRUSU6JRWK=
LB373-MEL-D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwM{[3PFkh|ryP NGXz[ppUSU6JRWK=
UACC-257 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojITWM2OD12LkO5OVM1KM7:TR?= NULx[YE{W0GQR1XS
MC-CAR NVfoe|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvQTWM2OD12LkSzPVkh|ryP NGTXVVRUSU6JRWK=
COLO-320-HSR NWPPWW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknXTWM2OD12LkS0OFI4KM7:TR?= M3T0UHNCVkeHUh?=
P30-OHK MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z5cmlEPTB;ND62OlU5OSEQvF2= MUfTRW5ITVJ?
UACC-812 NXG0[YVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlntTWM2OD12Lk[5NVYyKM7:TR?= MULTRW5ITVJ?
CTB-1 MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\Bd|FKSzVyPUSuO|E2PTVizszN M2XNfnNCVkeHUh?=
ALL-PO MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTRwOESwO|ch|ryP NFvZ[lFUSU6JRWK=
SK-MEL-2 NUHN[|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXZfo9KSzVyPUSuPFY6PTVizszN MoCyV2FPT0WU
TC-YIK M3XGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXWU|lKSzVyPUSuPVc6PDJizszN M2rrbnNCVkeHUh?=
NCI-H1882 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m0eGlEPTB;NT6wNlAxOSEQvF2= NVrLOId[W0GQR1XS
MHH-CALL-2 NVrYdGZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq5fYdtUUN3ME21MlA2ODR{IN88US=> MnLDV2FPT0WU
U-87-MG M3;vSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTVwMEm0OlYh|ryP M17QfnNCVkeHUh?=
NCI-H1092 M3PlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHETWM2OD13LkK2OVU2KM7:TR?= M2nsRnNCVkeHUh?=
TE-441-T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTVwMke4NkDPxE1? NHvMfmRUSU6JRWK=
SK-MEL-1 NGfOVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\1co9KSzVyPUWuNlkxPDRizszN MW\TRW5ITVJ?
EW-22 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX3TWM2OD13LkK5OFY3KM7:TR?= MVzTRW5ITVJ?
MZ7-mel M17nS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ricGlEPTB;NT60NFY6OSEQvF2= Mki5V2FPT0WU
LP-1 M4DwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T0TWlEPTB;NT60NVI6OSEQvF2= NVW1e45xW0GQR1XS
NCI-SNU-16 M1HiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInidZNKSzVyPUWuOlQxPzRizszN NEPKb5lUSU6JRWK=
LU-65 M3jBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTVwN{[zO|Mh|ryP NVP0PVFTW0GQR1XS
CW-2 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfDTWM2OD13Lki1PVU6KM7:TR?= MlXiV2FPT0WU
WSU-NHL NIOzOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjVTFBZUUN3ME21Mlk2OTd2IN88US=> NHnV[pBUSU6JRWK=
IST-MES1 NGPOd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTtZXp7UUN3ME21Mlk2PDR|IN88US=> MWXTRW5ITVJ?
U-266 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwOUiyNFIh|ryP M1;lbnNCVkeHUh?=
TALL-1 M{TYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\GTWlEPTB;Nj6xOFY5QCEQvF2= M{HLOnNCVkeHUh?=
Calu-6 NELkWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZwMUWzNVYh|ryP M3XsbXNCVkeHUh?=
MMAC-SF MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLqOFhHUUN3ME22MlE5PTV4IN88US=> MY\TRW5ITVJ?
NCI-H82 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS5SoRKSzVyPU[uNlA1QDlizszN NHTucYNUSU6JRWK=
RS4-11 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG5TWM2OD14LkK1PFk4KM7:TR?= MXfTRW5ITVJ?
SNU-C2B M2Hyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LBXGlEPTB;Nj60NFk3QSEQvF2= NEDyOmxUSU6JRWK=
BOKU M1y5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m4VGlEPTB;Nj60O|U6PyEQvF2= Ml3RV2FPT0WU
C8166 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnJelVyUUN3ME22MlU2QTF{IN88US=> NUSxbpRSW0GQR1XS
D-247MG Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z3cmlEPTB;Nz6wOFM1PyEQvF2= MnXSV2FPT0WU
EW-18 NYfMfXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPHVJE{UUN3ME23MlA4Ojl{IN88US=> NHK0WZdUSU6JRWK=
KG-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWThSGpKUUN3ME23MlYzPzN6IN88US=> NUTm[INOW0GQR1XS
REH MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXaTWM2OD15Lk[4NVA6KM7:TR?= NU\xfmlwW0GQR1XS
U-698-M NGLOS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnje4lKSzVyPUeuPFQ{OTVizszN MlnFV2FPT0WU
KP-N-RT-BM-1 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPXblZ7UUN3ME23Mlk{ODJ7IN88US=> NH\PPHNUSU6JRWK=
MS-1 M2H1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHGWlFCUUN3ME23Mlk3ODRzIN88US=> MkT4V2FPT0WU
SNU-C1 NXjkeXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PCT2lEPTB;Nz65PFE6OiEQvF2= M1PufnNCVkeHUh?=
SK-MM-2 M1r0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0ZWlEPTB;OD6yOlA3PSEQvF2= MVPTRW5ITVJ?
LAN-6 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vIcWlEPTB;OD6zNFAxOSEQvF2= MXfTRW5ITVJ?
NEC8 NXy3UYRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zoe2lEPTB;OD6zNFY6OSEQvF2= NEfwTYxUSU6JRWK=
NCI-H1770 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRThwM{iwNFIh|ryP NWHEbXdYW0GQR1XS
D-336MG Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDl[4psUUN3ME24MlQxOTF4IN88US=> NWrQUFVVW0GQR1XS
COLO-829 M{D0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml71TWM2OD16LkS4PFc6KM7:TR?= MlS3V2FPT0WU
LS-513 NF3ROoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHaV2RGUUN3ME24MlU6PTl7IN88US=> MkjCV2FPT0WU
YT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfVTWM2OD16Lk[yOFI4KM7:TR?= NFzKcolUSU6JRWK=
EW-24 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRThwN{[1OEDPxE1? MkjHV2FPT0WU
IST-SL1 M4\mNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nMfmlEPTB;OD64OlU1OyEQvF2= MVPTRW5ITVJ?
CA46 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTIUI1KSzVyPUiuPVUxQThizszN NVixOFZvW0GQR1XS
NCI-H1838 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwOUi2NFIh|ryP Mo\RV2FPT0WU
NCI-H719 M2jVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r3d2lEPTB;OT6yOVI4QSEQvF2= MnjxV2FPT0WU
HCE-T MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXBeHBKSzVyPUmuN|A5PTFizszN NFX6UG9USU6JRWK=
A498 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n0d2lEPTB;OT6zOlEzPCEQvF2= NEnyO3hUSU6JRWK=
LB831-BLC NIToT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTlwN{[1NlEh|ryP M3mzdXNCVkeHUh?=
SKM-1 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3JUllKSzVyPUmuPFU6PjNizszN NWqyPJVtW0GQR1XS
THP-1 NHPtXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHO[4ZKSzVyPUmuPVY6OThizszN NEDrVpRUSU6JRWK=
SHP-77 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFyLkSwO{DPxE1? NELOcHBUSU6JRWK=
EW-3 NHvaOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\YV2JYUUN3ME2xNE43Ojh7IN88US=> MojnV2FPT0WU
KY821 NVnBN3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1zMD63OlMh|ryP NEjQVI1USU6JRWK=
NCI-SNU-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSwSmhGUUN3ME2xNU4xOjF5IN88US=> NXPRWYpEW0GQR1XS
HCC2218 NWKxUo5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:4TWM2OD1zMT6zPVg3KM7:TR?= M1XZNXNCVkeHUh?=
IM-9 M4HD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m5OmlEPTB;MUGuOVExPiEQvF2= MkjSV2FPT0WU
NCI-H889 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXhNXVOUUN3ME2xNU42OzF|IN88US=> NYDRd4lbW0GQR1XS
HDLM-2 NX:2VFE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzrTWM2OD1zMj60NVU6KM7:TR?= MoTiV2FPT0WU
LB2518-MEL Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK4Z4M1UUN3ME2xNk43QDF3IN88US=> MmTiV2FPT0WU
NCI-H23 M1:zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzuWlVKSzVyPUGzMlI1OjVizszN NYfYZYxoW0GQR1XS
NB17 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfvTWM2OD1zMz60OVc6KM7:TR?= MXzTRW5ITVJ?
NCI-H322M M1uwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXqTWM2OD1zND60NFY5KM7:TR?= MVvTRW5ITVJ?
SUP-T1 M1S0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKTWM2OD1zND60NVMh|ryP NXHmWIw5W0GQR1XS
ES3 NEjIe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXTZm1KSzVyPUG1MlA4ODNizszN Mm\aV2FPT0WU
ES5 NHznW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[wfGlEPTB;MUWuNFc5PyEQvF2= NUHUTXR7W0GQR1XS
NCI-H1650 NXTSRpNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF3LkS5O|kh|ryP Mof0V2FPT0WU
NCI-H226 M{POemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF3Lki3Olgh|ryP NV7XbYhiW0GQR1XS
COR-L88 M2TZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF4LkOxOEDPxE1? MknkV2FPT0WU
SCC-15 M4qyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF4LkO4Olkh|ryP M3\EUXNCVkeHUh?=
GOTO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYntbJhGUUN3ME2xOk41Pzl|IN88US=> M37ISHNCVkeHUh?=
SIMA NYXsVJYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTGbG9xUUN3ME2xOk41QDB{IN88US=> MoLqV2FPT0WU
NCI-H1299 NIfXboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPXeVdqUUN3ME2xO{4yPTlzIN88US=> MkLvV2FPT0WU
NCI-H1581 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\wZppKSzVyPUG3MlQzOTlizszN NFnOUnFUSU6JRWK=
MHH-NB-11 M2XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn36TWM2OD1zNz65Olg{KM7:TR?= NXz6eI5MW0GQR1XS
MFM-223 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX5TWM2OD1zOD6wOVM5KM7:TR?= NInwfHRUSU6JRWK=
ES7 NFrIWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TqfWlEPTB;MUiuOVQ{OSEQvF2= M1vXUnNCVkeHUh?=
JVM-3 NHvGfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLLO3U1UUN3ME2xPE44OTdizszN MV;TRW5ITVJ?
RL MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvub5BwUUN3ME2yNE4{QDhizszN NXKxNnZ3W0GQR1XS
EC-GI-10 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJzLkKwOFEh|ryP M3PabnNCVkeHUh?=
LNCaP-Clone-FGC NHTQflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\TTWM2OD1{MT62O|Y5KM7:TR?= MnvFV2FPT0WU
IMR-5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3FTWM2OD1{MT64OFk1KM7:TR?= NIrhRmJUSU6JRWK=
KP-N-YS NUPDbok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjpU5pKSzVyPUKxMlg4PSEQvF2= MVPTRW5ITVJ?
Mo-T M4jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HEeGlEPTB;MkKuNlE5PSEQvF2= MWnTRW5ITVJ?
NCI-H128 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ|LkW4OVMh|ryP M{HqZXNCVkeHUh?=
RH-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjFcWFKSzVyPUKzMlc5PjZizszN NFLvN2hUSU6JRWK=
NCI-H2171 NIrGbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ2LkK0PFUh|ryP MUHTRW5ITVJ?
RPMI-8866 M2LLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ4Lke0NkDPxE1? NGKweZdUSU6JRWK=
SK-N-FI MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrjVHZYUUN3ME2yO{4{QDFzIN88US=> M1jqOHNCVkeHUh?=
LOXIMVI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ5LkiwOVEh|ryP MWTTRW5ITVJ?
P31-FUJ MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ZNJNKSzVyPUOxMlU{PzRizszN MlnJV2FPT0WU
KMS-12-PE MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR7LkWzNFIh|ryP NGnXUpJUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1
NCT03298958 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio December 1 2018 Phase 3
NCT03433183 Not yet recruiting Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca December 2018 Phase 2
NCT03721614 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. December 1 2018 Not Applicable
NCT03203525 Not yet recruiting Liver Cancer M.D. Anderson Cancer Center|NovoCure Ltd. December 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID